Gilead Sciences (GILD) is scheduled to report first-quarter earnings after the market close on Thursday, with investors and analysts closely watching the performance of its flagship HIV franchise while weighing the potential for headline risk from activist campaigns. The stock has fallen 7.6 percent over the past month, underperforming the broader market as investors await clarity on growth drivers beyond the company's core portfolio.
"Gilead's Earnings per Share Expected to Be Up 52% as Florida's and other States' AIDS Drug Programs Falters," the AIDS Healthcare Foundation (AHF), a vocal critic of the company, said in a press release issued May 5. The statement highlights a significant reputational risk for Gilead, even as the group's profit growth estimate diverges sharply from Wall Street consensus.
Analysts surveyed by Zacks Investment Research expect Gilead to report adjusted earnings of $1.89 per share, representing a 4.4 percent increase from the year-ago quarter. The consensus revenue forecast is $6.89 billion, up 3.4 percent year-over-year. The AHF's provocative claim draws a contrast that investors will have to parse, weighing the company's financial performance against potential public and political pressure.
Key product sales forecasts compiled by analysts show an expected $2.56 billion in U.S. revenue for the HIV treatment Biktarvy, a 3.3 percent year-over-year increase. However, other products face headwinds, with analysts projecting sales declines for the liver disease treatment Vemlidy and the cell therapy Yescarta.
Valuation: A Tale of Two Narratives
The valuation case for Gilead presents a stark contrast between bullish long-term models and more cautious near-term outlooks. An analysis by Simply Wall St suggests the stock is significantly undervalued based on a discounted cash flow (DCF) model, which estimates an intrinsic value of approximately $278 per share—a 53.7 percent discount to its current price of around $128.
This view is supported by a "bull case" narrative on the platform that sees a fair value of $157.43, assuming annual revenue growth of 4.48 percent driven by a strong HIV and oncology portfolio.
Conversely, a "bear case" narrative sets a more conservative fair value of $126.09, just below the current price. This view assumes revenue growth slows to 2.16 percent a year, held back by competition in HIV and slower-than-expected progress in its oncology pipeline. This highlights the pressure on Gilead to execute on its pipeline to justify its current valuation.
Pipeline and Protests
Beyond the top-line numbers, investors will look for updates on Gilead's pipeline and strategic partnerships. The company announced an expanded collaboration with Tempus AI in early April to advance AI-driven clinical research, a move aimed at bolstering its long-term growth prospects in oncology.
Still, the upcoming report will be framed by the AHF's campaign, which alleges a link between Gilead's profitability and the financial instability of state-run AIDS Drug Assistance Programs (ADAPs). While the direct financial impact of such a campaign is difficult to quantify, it creates significant headline risk and could attract scrutiny from lawmakers at a time when drug pricing remains a sensitive political issue. Investors will be listening for any commentary from management on drug pricing, patient access programs, and the sustainability of its HIV franchise revenues.
This article is for informational purposes only and does not constitute investment advice.
